TREATMENT
Review: short-term medical use of cannabis increases risk of non-serious adverse effects
| The first 150 words of the full text of this article appear below. |
M A Ware
Dr M A Ware, Montreal General Hospital, Montreal, Quebec, Canada; mark.ware@mail.mcgill.ca
Is medical use of cannabis associated with an increased risk of adverse effects?
Studies selected reported adverse events associated with medical use of cannabis for pain or chemotherapy-induced nausea in patients with chronic diseases such as multiple sclerosis, neuropathic pain, or cancer. Outcomes were serious and non-serious adverse events.
Ovid Medline, PsycINFO, and EMBASE/Excerpta Medica (to Oct 2007), and reference lists were searched for randomised controlled trials (RCTs), observational studies, and case reports. 23 RCTs (n = 2087) and 8 observational studies met the selection criteria. An oral cannabinoid product was used in 15 RCTs, and an oromucosal cannabinoid spray was used in 8 RCTs. Median duration of use was 2 weeks (range 8 h to 12 mo). No trial on medical use of cannabis by smoking reported adverse events.
Meta-analysis of 23 RCTs showed that
University of British Columbia, Vancouver, British Columbia, Canada
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
